HCM
Price
$15.81
Change
+$0.12 (+0.76%)
Updated
Jul 3 closing price
Capitalization
2.88B
33 days until earnings call
SFOSF
Price
$1.96
Change
-$0.01 (-0.51%)
Updated
Jun 2 closing price
Capitalization
10.9B
Interact to see
Advertisement

HCM vs SFOSF

Header iconHCM vs SFOSF Comparison
Open Charts HCM vs SFOSFBanner chart's image
HUTCHMED (China)
Price$15.81
Change+$0.12 (+0.76%)
Volume$59.32K
Capitalization2.88B
Shanghai Fosun Pharmaceutical Group
Price$1.96
Change-$0.01 (-0.51%)
Volume$500
Capitalization10.9B
HCM vs SFOSF Comparison Chart in %
Loading...
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SFOSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HCM vs. SFOSF commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HCM is a StrongBuy and SFOSF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (HCM: $15.81 vs. SFOSF: $1.96)
Brand notoriety: HCM and SFOSF are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: HCM: 74% vs. SFOSF: 69%
Market capitalization -- HCM: $2.88B vs. SFOSF: $10.9B
HCM [@Pharmaceuticals: Other] is valued at $2.88B. SFOSF’s [@Pharmaceuticals: Other] market capitalization is $10.9B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HCM’s FA Score shows that 1 FA rating(s) are green whileSFOSF’s FA Score has 1 green FA rating(s).

  • HCM’s FA Score: 1 green, 4 red.
  • SFOSF’s FA Score: 1 green, 4 red.
According to our system of comparison, both HCM and SFOSF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HCM’s TA Score shows that 5 TA indicator(s) are bullish while SFOSF’s TA Score has 2 bullish TA indicator(s).

  • HCM’s TA Score: 5 bullish, 5 bearish.
  • SFOSF’s TA Score: 2 bullish, 2 bearish.
According to our system of comparison, HCM is a better buy in the short-term than SFOSF.

Price Growth

HCM (@Pharmaceuticals: Other) experienced а +3.06% price change this week, while SFOSF (@Pharmaceuticals: Other) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.13%. For the same industry, the average monthly price growth was +3.08%, and the average quarterly price growth was +93.03%.

Reported Earning Dates

HCM is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.13% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SFOSF($10.9B) has a higher market cap than HCM($2.88B). HCM has higher P/E ratio than SFOSF: HCM (27.95) vs SFOSF (11.75). HCM YTD gains are higher at: 9.715 vs. SFOSF (8.593). SFOSF has higher annual earnings (EBITDA): 6.12B vs. HCM (67.3M). SFOSF has more cash in the bank: 16.1B vs. HCM (886M). HCM has less debt than SFOSF: HCM (86.1M) vs SFOSF (30.8B). SFOSF has higher revenues than HCM: SFOSF (44.4B) vs HCM (838M).
HCMSFOSFHCM / SFOSF
Capitalization2.88B10.9B26%
EBITDA67.3M6.12B1%
Gain YTD9.7158.593113%
P/E Ratio27.9511.75238%
Revenue838M44.4B2%
Total Cash886M16.1B6%
Total Debt86.1M30.8B0%
FUNDAMENTALS RATINGS
HCM vs SFOSF: Fundamental Ratings
HCM
SFOSF
OUTLOOK RATING
1..100
8650
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8880
PRICE GROWTH RATING
1..100
5353
P/E GROWTH RATING
1..100
580
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SFOSF's Valuation (23) in the null industry is significantly better than the same rating for HCM (89) in the Pharmaceuticals Major industry. This means that SFOSF’s stock grew significantly faster than HCM’s over the last 12 months.

SFOSF's Profit vs Risk Rating (100) in the null industry is in the same range as HCM (100) in the Pharmaceuticals Major industry. This means that SFOSF’s stock grew similarly to HCM’s over the last 12 months.

SFOSF's SMR Rating (80) in the null industry is in the same range as HCM (88) in the Pharmaceuticals Major industry. This means that SFOSF’s stock grew similarly to HCM’s over the last 12 months.

SFOSF's Price Growth Rating (53) in the null industry is in the same range as HCM (53) in the Pharmaceuticals Major industry. This means that SFOSF’s stock grew similarly to HCM’s over the last 12 months.

HCM's P/E Growth Rating (5) in the Pharmaceuticals Major industry is significantly better than the same rating for SFOSF (80) in the null industry. This means that HCM’s stock grew significantly faster than SFOSF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HCMSFOSF
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
62%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
57%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
47%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
61%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
52%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
45%
Advances
ODDS (%)
Bullish Trend 2 days ago
73%
N/A
Declines
ODDS (%)
Bearish Trend 5 days ago
81%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SFOSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BBUS113.300.99
+0.88%
JPMorgan BetaBuilders US Equity ETF
FRI27.330.08
+0.29%
First Trust S&P REIT ETF
IBIB25.280.02
+0.08%
iShares iBonds Oct 2025 Term Tips ETF
MLDR49.17N/A
N/A
Global X Intermediate-Term Trsy Lddr ETF
DSU10.63-0.02
-0.19%
Blackrock Debt Strategies Fund

SFOSF and

Correlation & Price change

A.I.dvisor tells us that SFOSF and CANN have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SFOSF and CANN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SFOSF
1D Price
Change %
SFOSF100%
N/A
CANN - SFOSF
21%
Poorly correlated
+4.34%
HCM - SFOSF
21%
Poorly correlated
+0.76%
MSTH - SFOSF
21%
Poorly correlated
N/A
SGIOF - SFOSF
11%
Poorly correlated
N/A
RAFA - SFOSF
9%
Poorly correlated
N/A
More